First Header Logo Second Header Logo

Connection

Ryan Drenan to Mice, Transgenic

This is a "connection" page, showing publications Ryan Drenan has written about Mice, Transgenic.
Connection Strength

0.928
  1. Peng C, Yan Y, Kim VJ, Engle SE, Berry JN, McIntosh JM, Neve RL, Drenan RM. Gene editing vectors for studying nicotinic acetylcholine receptors in cholinergic transmission. Eur J Neurosci. 2019 08; 50(3):2224-2238.
    View in: PubMed
    Score: 0.149
  2. Berry JN, Engle SE, McIntosh JM, Drenan RM. a6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity. Neuroscience. 2015 Sep 24; 304:161-75.
    View in: PubMed
    Score: 0.121
  3. Shih PY, Engle SE, Oh G, Deshpande P, Puskar NL, Lester HA, Drenan RM. Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula. J Neurosci. 2014 Jul 16; 34(29):9789-802.
    View in: PubMed
    Score: 0.112
  4. Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM. Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function a6* nAChRs. J Neurochem. 2014 Apr; 129(2):315-27.
    View in: PubMed
    Score: 0.108
  5. Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, Wang Y, Grady SR, McIntosh JM, Marks MJ, Lester HA, Drenan RM. a6* nicotinic acetylcholine receptor expression and function in a visual salience circuit. J Neurosci. 2012 Jul 25; 32(30):10226-37.
    View in: PubMed
    Score: 0.098
  6. Cohen BN, Mackey ED, Grady SR, McKinney S, Patzlaff NE, Wageman CR, McIntosh JM, Marks MJ, Lester HA, Drenan RM. Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior. Neuroscience. 2012 Jan 03; 200:31-41.
    View in: PubMed
    Score: 0.093
  7. Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, Marks MJ, Miwa JM, Lester HA. Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci. 2010 Jul 21; 30(29):9877-89.
    View in: PubMed
    Score: 0.085
  8. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron. 2008 Oct 09; 60(1):123-36.
    View in: PubMed
    Score: 0.075
  9. Parker RL, O'Neill HC, Henley BM, Wageman CR, Drenan RM, Marks MJ, Miwa JM, Grady SR, Lester HA. Deletion of lynx1 reduces the function of a6* nicotinic receptors. PLoS One. 2017; 12(12):e0188715.
    View in: PubMed
    Score: 0.036
  10. Bordia T, McGregor M, McIntosh JM, Drenan RM, Quik M. Evidence for a role for a6(*) nAChRs in l-dopa-induced dyskinesias using Parkinsonian a6(*) nAChR gain-of-function mice. Neuroscience. 2015 Jun 04; 295:187-97.
    View in: PubMed
    Score: 0.029
  11. Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ. Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology. 2010 Jun; 58(7):1054-66.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.